A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1282
- Registration Number
- NCT01369355
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 640
- Registration Number
- NCT01369342
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 769
- Registration Number
- NCT01369329
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01366664
A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT01366651
Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT01362699
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01343303
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 579
- Registration Number
- NCT01343277
An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 279
- Registration Number
- NCT01340664
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT01323205
© Copyright 2024. All Rights Reserved by MedPath